Background: The timing of cardiovascular risks associated with the use of cyclooxygenase-2
(COX-2) inhibitors is unclear. Using data collected in a previous population-based cohort …

Background—Although cyclooxygenase-2 inhibitors (coxibs) were developed to cause less
gastrointestinal hemorrhage than nonselective nonsteroidal antiinflammatory drugs …

Background: Cyclooxygenase-2 (COX-2) selective inhibitors have been marketed since
1999 as safer alternatives to nonsteroidal anti-inflammatory drugs (NSAIDs). Debate about …

Abstract Background and Objective: The search for NSAIDs with less gastrointestinal toxicity
led to the introduction of the selective cyclo-oxygenase-2 (COX-2) inhibitors. However …

Background Recent debate has emerged regarding the cardiovascular safety of selective
cyclooxygenase 2 inhibitors and the possible cardioprotective effect of naproxen sodium …

Purpose To evaluate the association between rofecoxib, celecoxib, diclofenac, and
ibuprofen and the risk of hospitalization for acute myocardial infarction (AMI) in an elderly …

Background: Cyclo-oxygenase-2 selective inhibitors have been associated with
cardiovascular side effects, but previous studies have generally excluded people with …

Background COX-2 selective inhibitors are associated with myocardial infarction (MI). We
sought to determine whether population health monitoring would have revealed the effect of …

Background—The cardiovascular safety of cyclooxygenase (COX)-2–selective nonsteroidal
antiinflammatory drugs (NSAIDs) has come under scrutiny after the withdrawal of rofecoxib …

Background: Studies have postulated that cyclooxygenase-2 (COX-2) selective inhibitors
affect cardiovascular risk through various mechanisms. Some of these mechanisms could …